Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun:81:103885.
doi: 10.1016/j.breast.2025.103885. Epub 2025 Jan 21.

Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy?

Wiebren Tjalma  1 , Laure-Anne Teuwen  2 , Sevilay Altintas  2 , Konstantinos Papadimitriou  2
Affiliations

Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy?

Wiebren Tjalma et al. Breast. 2025 Jun.

Abstract

The standard of care for HER2-positive and hormone receptor-positive breast cancer patients who receive neoadjuvant chemotherapy (NACT) combined with trastuzumab, with or without pertuzumab, is to continue with adjuvant T-DM1 in cases of an incomplete response according to KATHERINE trial results. However, the optimal management for patients with residual disease with loss of HER2 expression is not widely studied. Loss of HER2 expression after NACT with anti HER2 is a rarer event with questionable value both as a predictive prognostic marker.

Keywords: Breast cancer; Guideline; HER 2; Partial response; Pertuzumab; Trastuzumab; Trastuzumab emtansine.

PubMed Disclaimer

References

    1. von Minckwitz G., Huang C.S., Mano M.S., et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. Feb 14 2019;380(7):617–628. doi: 10.1056/NEJMoa1814017. - DOI - PubMed
    1. Loibl S., Huang C.-S., Mano M.S., et al. Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analysis from KATHERINE. Ann Oncol. 2020;(31) Abstract 960. - PubMed
    1. Branco F.P., Machado D., Silva F.F., et al. Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer. Am J Transl Res. 2019;11(9):6110–6116. - PMC - PubMed
    1. Guarneri V., Dieci M.V., Barbieri E., et al. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol. Dec 2013;24(12):2990–2994. doi: 10.1093/annonc/mdt364. - DOI - PubMed
    1. Tarantino P., Ajari O., Graham N., et al. Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer. Eur J Cancer. Apr 2024;201 doi: 10.1016/j.ejca.2024.113920. - DOI - PubMed

MeSH terms